S-3/A
As
filed with the Securities and Exchange Commission on May 19, 2009
Registration
No. 333-158405
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Amendment No. 1 to
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
AMICUS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
20-0422823 |
(State of incorporation)
|
|
(IRS Employer Identification Number) |
6 Cedar Brook Drive, Cranbury, NJ 08512
(609) 662-2000
(Address, including zip code, and telephone number, including area code, of registrants principal
executive offices)
John F. Crowley
Chief Executive Officer
Amicus Therapeutics, Inc.
6 Cedar Brook Drive
Cranbury, New Jersey 08512
(609) 662-2000
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Approximate date of commencement of proposed sale to the public:
From time to time after the effective date of this Registration Statement.
If the only securities being registered on this Form are being offered pursuant to dividend or
interest reinvestment plans, please check the following box. o
If any of the securities being registered on this Form are to be offered on a delayed or
continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities
offered only in connection with dividend or interest reinvestment plans, check the following
box. þ
If this Form is filed to register additional securities for an offering pursuant to Rule
462(b) under the Securities Act, please check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same
offering. o
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities
Act, please check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. o
If this Form is a registration statement pursuant to General Instruction I.D. or a
post-effective amendment thereto that shall become effective upon filing with the Commission
pursuant to Rule 462(e) under the Securities Act, check the following box. o
If this Form is a post-effective amendment to a registration statement filed pursuant to
General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the
Securities Act, check the following box. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,
a non-accelerated filer, or a smaller reporting company.
See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer o |
|
Accelerated filer o |
|
Non-accelerated filer þ
(Do not check if a smaller reporting company) |
|
Smaller reporting company o |
CALCULATION OF REGISTRATION FEE (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of each class of securities to be registered |
|
|
Proposed maximum offering price (1)(2) |
|
|
Amount of registration fee (2) |
|
|
Common Stock (3) |
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock (4) |
|
|
|
|
|
|
|
|
|
|
|
|
Warrants (5) |
|
|
|
|
|
|
|
|
|
|
|
|
Debt securities (6) |
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
$ |
100,000,000 |
|
|
|
$ |
5,580 |
(7) |
|
|
|
|
|
(1) |
|
In no event will the aggregate offering price of all securities issued from time to time by the
registrant or sold by the selling stockholders under this registration statement exceed $100,000,000 or
its equivalent in any other currency, currency units, or composite currency or currencies. The
securities covered by this registration statement to be sold by the registrant may be sold separately,
together, or as units with other securities registered under this registration statement. The
securities to be resold by the selling stockholders will be shares of common stock only. |
|
(2) |
|
The proposed maximum aggregate price has been estimated solely for the purpose of calculating the
registration fee pursuant to Rule 457(o) under the Securities Act. |
|
(3) |
|
Subject to note (1), this registration statement covers an indeterminate amount of common stock (with
accompanying purchase rights, if any), as may be sold, from time to time, at indeterminate prices, by
the registrant or the selling stockholders, as the case may be. |
|
(4) |
|
Subject to note (1), this registration statement covers an indeterminate number of shares of preferred
stock (with accompanying purchase rights, if any), as may be sold, from time to time, at indeterminate
prices, by the registrant. Also covered is such an indeterminate amount of common stock (with
accompanying purchase rights, if any) (i) as may be issuable or deliverable upon conversion of shares of
preferred stock, and (ii) as may be required for delivery upon conversion of shares of preferred stock
as a result of anti-dilution provisions. |
|
(5) |
|
Subject to note (1), this registration statement covers an indeterminate amount and number of warrants
representing rights to purchase common stock, preferred stock and/or debt securities registered under
this registration statement, as may be sold, from time to time, at indeterminate prices by the
registrant. Also covered is an indeterminate amount of common stock and preferred stock (in each case,
with accompanying purchase rights, if any) and debt securities (i) as may be issuable or deliverable
upon exercise of warrants and (ii) as may be required for delivery upon exercise of any warrants as a
result of anti-dilution provisions. |
|
(6) |
|
Subject to note (1), this registration statement covers an indeterminate amount of debt securities, as
may be sold, from time to time, at indeterminate prices by the registrant. If any debt securities are
issued at an original issue discount, then the offering price shall be in such greater principal amount
as shall result in an aggregate initial offering price not to exceed $100,000,000. Also covered is an
indeterminate amount of common stock and preferred stock (in each case, with accompanying purchase
rights, if any) (i) as may be issuable or deliverable upon exercise or conversion of debt securities and
(ii) as may be required for delivery upon exercise or conversion of debt securities as a result of
anti-dilution provisions. |
|
(7) |
|
The registration fee of $5,580 has been previously paid with
this Registration Statement based on an estimate of the aggregate
offering price. |
We hereby amend this registration statement on such date or dates as may be necessary to delay its
effective date until we shall file a further amendment which specifically states that this
registration statement shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933 or until this registration statement shall become effective on such date as
the Commission, acting pursuant to said Section 8(a), may determine.
The information contained in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission
becomes effective. This prospectus is not an offer to sell these securities and we are not
soliciting offers to buy these securities in any jurisdiction where such offer or sale is not
permitted.
Subject
to Completion, Dated May 19, 2009
PROSPECTUS
$100,000,000
AMICUS THERAPEUTICS, INC.
Common Stock
Preferred Stock
Warrants
Debt Securities
We may offer to the public from time to time in one or more series or issuances:
|
|
|
shares of our common stock; |
|
|
|
|
shares of preferred stock; |
|
|
|
|
warrants to purchase shares of our common stock, preferred stock and/or debt securities; |
|
|
|
|
debt securities consisting of debentures, notes or other evidences of indebtedness; or |
|
|
|
|
any combination of these securities. |
Selling stockholders may also offer shares of our common stock from time to time
in connection with this offering.
This prospectus provides a general description of the securities that we or the selling
stockholders may offer. Each time that securities are sold under this prospectus, we will provide
specific terms of the securities offered in a supplement to this prospectus. The prospectus
supplement may also add, update or change information contained in this prospectus. This prospectus
may not be used to consummate a sale of securities unless accompanied by the applicable prospectus
supplement. You should read both this prospectus and the applicable prospectus supplement together
with additional information described under the heading Where You Can Find More Information
before you make your investment decision.
Securities sold under this prospectus shall be sold directly to purchasers or through agents
on our behalf or on behalf of the selling stockholders or through underwriters or dealers as
designated from time to time. Each time a selling stockholder sells or disposes shares of common stock pursuant to this offering, the selling stockholder
is required to provide you with this prospectus and a prospectus supplement containing specific information about the selling stockholder and the terms of the
offering. If any agents or underwriters are involved in the sale of any of
these securities, the applicable prospectus supplement will provide the names of the agents or
underwriters and any applicable fees, commissions or discounts.
Our common stock is traded on the Nasdaq Global Market under the symbol FOLD. On May 11,
2009, the closing price of our common stock was $7.50.
As of March 23, 2009, the aggregate market value of our outstanding common stock held by
non-affiliates was approximately $106,307,120, based on 22,643,056 shares of outstanding common
stock, of which approximately 10,630,712 shares are held by non-affiliates, and a per share price
of $10.00 based on the closing sale price of our common stock on March 23, 2009. As of the date
hereof, we have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during
the prior 12 calendar month period that ends on and includes the date hereof.
Investing in our securities involves certain risks. Before investing, you should refer to the
risk factors on page 3 of this prospectus, included in our periodic reports, in prospectus
supplements and in other information filed by us with the Securities and Exchange Commission.
These securities have not been approved by the Securities and Exchange Commission or any state
securities commission, nor have these organizations determined that this prospectus is accurate or
complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is , 2009.
TABLE OF CONTENTS
Prospectus
|
|
|
|
|
|
|
Page |
|
|
|
1 |
|
|
|
|
2 |
|
|
|
|
3 |
|
|
|
|
3 |
|
|
|
|
4 |
|
|
|
|
4 |
|
|
|
|
5 |
|
|
|
|
6 |
|
|
|
|
8 |
|
|
|
|
8 |
|
|
|
|
9 |
|
|
|
|
10 |
|
|
|
|
11 |
|
|
|
|
15 |
|
|
|
|
15 |
|
|
|
|
15 |
|
EX-23.2 |
ABOUT THIS PROSPECTUS
This prospectus is a part of a registration statement that we filed with the Securities and
Exchange Commission, or the SEC, using a shelf registration process. Under this shelf
registration process we may offer to sell any of the securities, or any combination of the
securities, described in this prospectus and the selling stockholders may offer to sell common
stock, in each case in one or more offerings up to a total dollar amount of $100,000,000.
This prospectus provides you only with a general description of the securities we or the
selling stockholders may offer. Each time securities are sold under this shelf registration, we
will provide a prospectus supplement that will contain specific information about the terms of
those securities and the terms of that offering. The prospectus supplement may also add, update or
change information contained in this prospectus. You should read both this prospectus and any
prospectus supplement, including all documents incorporated herein by reference, together with the
additional information described under Where You Can Find More Information below.
The information contained in this prospectus is not complete and may be changed. You should
rely only on the information provided in or incorporated by reference in this prospectus or in any
prospectus supplement, or documents to which we otherwise refer you. We have not authorized anyone
else to provide you with different information.
We have not authorized any dealer, agent or other person to give any information or to make
any representation other than those contained or incorporated by reference in this prospectus and
any accompanying prospectus supplement. You must not rely upon any information or representation
not contained or incorporated by reference in this prospectus or an accompanying prospectus
supplement. This prospectus and the accompanying prospectus supplement, if any, do not constitute
an offer to sell or the solicitation of an offer to buy any securities other than the registered
securities to which they relate, nor do this prospectus and the accompanying prospectus supplement
constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction
to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You
should not assume that the information contained in this prospectus and the accompanying prospectus
supplement, if any, is accurate on any date subsequent to the date set forth on the front of the
document or that any information we have incorporated by reference is correct on any date
subsequent to the date of the document incorporated by reference, even though this prospectus and
any accompanying prospectus supplement is delivered or securities are sold on a later date.
References in this prospectus to the terms the Company, Amicus, we, our and us or other
similar terms mean Amicus Therapeutics, Inc., unless we state otherwise or the context indicates
otherwise.
THE COMPANY
We are a clinical-stage biopharmaceutical company focused on the discovery, development and
commercialization of a new class of orally-administered, small molecule drugs, known as
pharmacological chaperones, for the treatment of a range of human genetic diseases. Our lead
product candidates in development are Amigal (migalastat hydrochloride) for Fabry disease, Plicera
(afegostat tartrate) for Gaucher disease and AT2220 (1-deoxynojirimycin HCl) for Pompe disease. We
completed our Phase 2 clinical trials of Amigal and are currently conducting Phase 2 clinical
trials of Plicera. We recently suspended a Phase 2 clinical trial of AT2220 and the IND is on
clinical hold pending FDA agreement to allow the Company to resume clinical development. Although
Fabry, Gaucher and Pompe are relatively rare diseases, they represent substantial commercial
markets due to the severity of the symptoms and the chronic nature of the diseases. The worldwide
net product sales for the five currently approved therapeutics to treat Fabry, Gaucher and Pompe
disease were approximately $2.2 billion in 2008, as publicly reported by the companies that market
these therapeutics.
Our goal is to become a leading biopharmaceutical company focused on the discovery,
development and commercialization of pharmacological chaperone therapies for the treatment of a
wide range of human diseases. Our initial clinical efforts are currently focused on developing
pharmacological chaperones for the treatment of lysosomal storage disorders, which are chronic
genetic diseases, such as Fabry, Gaucher and Pompe that frequently result in severe symptoms. We
also believe our technology may be broadly applicable to other diseases for which protein
stabilization and improved folding may be beneficial, including certain neurodegenerative and
genetically-based metabolic disorders.
Fabry, Gaucher and Pompe are among certain human diseases which result from mutations in
specific genes that, in many cases, lead to the production of proteins with reduced stability.
Proteins with such mutations may not fold into their correct three-dimensional shape and are
generally referred to as misfolded proteins. Misfolded proteins are often recognized by cells as
having defects and, as a result, may be eliminated prior to reaching their intended location in the
cell. The reduced biological activity of these proteins leads to impaired cellular function and
ultimately to disease.
Our novel approach to the treatment of human genetic diseases consists of using
pharmacological chaperones that selectively bind to the target protein; increasing the stability of
the protein and helping it fold into the correct three-dimensional shape. This allows proper
trafficking of the protein, thereby increasing protein activity, improving cellular function and
potentially reducing cell stress.
The current standard of treatment for Fabry, Gaucher and Pompe is enzyme replacement therapy
(ERT). This therapy compensates for the reduced level of activity of specialized proteins called
enzymes through regular infusions of recombinant enzyme. Instead of adding enzymes from an external
source by intravenous infusion, our approach uses small molecule, orally-administered
pharmacological chaperones to restore the function of the enzyme that is already made by the
patients own body. We believe our product candidates may have advantages relative to ERT relating
to bio-distribution and ease of use, potentially improving treatment of these diseases.
In order to further the development of our pharmacological chaperone therapies and share the
costs of such development, in November 2007, we entered into a strategic collaboration with Shire
Pharmaceuticals Ireland Ltd. (Shire), a subsidiary of Shire plc, to jointly develop our three lead
pharmacological chaperone compounds for lysosomal storage disorders. Shire will receive rights to
commercialize these products outside of the United States (U.S.). We retain all rights to
commercialize these products in the U.S.
Our principal executive offices are located at 6 Cedar Brook Drive, Cranbury, NJ 08512, and
our phone number is (609) 662-2000.
-2-
RISK FACTORS
Investing in our securities involves risk. The prospectus supplement applicable to each
offering of our securities will contain a discussion of the risks applicable to an investment in
us. Prior to making a decision about investing in our securities, you should carefully consider the
specific factors discussed under the heading Risk Factors in the applicable prospectus
supplement, together with all of the other information contained or incorporated by reference in
the prospectus supplement or appearing or incorporated by reference in this prospectus. You should
also consider the risks, uncertainties and assumptions discussed under the heading Risk Factors
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed on February 6,
2009, with the SEC, which is incorporated herein by reference, and may be amended, supplemented or
superseded from time to time by other reports we file with the SEC in the future. The risks and
uncertainties we have described are not the only ones we face. Additional risks and uncertainties
not presently known to us or that we currently deem immaterial may also affect our operations.
FORWARD-LOOKING STATEMENTS
This prospectus, any prospectus supplement and the other documents we have filed with the SEC
that are incorporated herein by reference contain forward-looking statements that involve
substantial risks and uncertainties. All statements, other than statements of historical facts,
regarding our strategy, future operations, future financial position, future revenues, projected
costs, prospects, plans, objectives of management or other financial items are forward-looking
statements. The words anticipate, believe, estimate, expect, intend, may, plan,
predict, project, will, would and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying
words.
We may not actually achieve the plans, intentions or expectations disclosed in our
forward-looking statements, and you should not place undue reliance on our forward-looking
statements. Actual results or events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements we make. We have included important
factors in the cautionary statements included in this prospectus, particularly as set forth and
incorporated by reference in the Risk Factors section above, that we believe could cause actual
results or events to differ materially from the forward-looking statements that we make. Our
forward-looking statements do not reflect the potential impact of any future acquisitions, mergers,
dispositions, joint ventures, collaborations or investments we may make.
You should read this prospectus, any supplements to this prospectus and the documents that we
incorporate by reference in this prospectus completely and with the understanding that our actual
future results may be materially different from what we expect. We do not assume any obligation to
update any forward-looking statements.
-3-
USE OF PROCEEDS
Except as otherwise provided in the applicable prospectus supplement, we intend to use the net
proceeds from the sale of the securities covered by this prospectus for general corporate purposes,
which may include working capital, capital expenditures, research and development expenditures,
clinical trial expenditures, commercial expenditures, acquisitions of new technologies or
businesses, and investments. Additional information on the use of net proceeds from the sale of
securities covered by this prospectus may be set forth in the prospectus supplement relating to the
specific offering. We will not receive any of the proceeds from the sale of any securities offered
pursuant to this prospectus by any selling stockholder.
RATIO OF EARNINGS TO COMBINED FIXED CHARGES (1)
The following table sets forth our ratio of earnings to fixed charges on a historical basis
for the periods indicated. For purposes of this calculation, earnings consists of net loss from
continuing operations plus fixed charges. Fixed charges consist of the sum of interest expense
and the estimate of interest within rental expense.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, |
|
|
2004 |
|
2005 |
|
2006 |
|
2007 |
|
2008 |
Ratio of Earnings
to Fixed Charges
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deficiency of
Earnings Available
to Cover Fixed Charges
(in millions) |
|
$ |
8.2 |
|
|
$ |
19.6 |
|
|
$ |
45.5 |
|
|
$ |
40.2 |
|
|
$ |
38.5 |
|
|
|
|
(1) |
|
For the years ended December 31, 2004, 2005, 2006, 2007 and 2008, earnings were insufficient
to cover fixed charges by $8.8 million, $20.0 million, $46.3 million, $41.2 million and $39.4
million, respectively. |
-4-
SELLING STOCKHOLDERS
This
prospectus also relates to the possible resale of shares of our common stock which were previously
acquired by certain persons through several private placements of our convertible preferred stock
completed by us prior to our initial public offering (IPO) in 2007, which were all converted to
shares of our common stock in connection with the IPO, and through private placements of our common
stock completed by us prior to the filing of the Registration Statement of which this prospectus is a
part. In connection with such private placements, these persons have registration rights with respect
to their shares as described further below under the heading Certain Relationships and Related Party
Transactions. Information about selling stockholders, if any, including their identities and the number
of shares of common stock to be registered on their behalf, will be set forth in a prospectus supplement,
in a post-effective amendment or in filings we make with the Securities and Exchange Commission under the
Securities Exchange Act of 1934, as amended, that are incorporated by reference into this prospectus.
Selling stockholders shall not sell any shares of our common stock pursuant to this prospectus until we
have identified such selling stockholders and the shares being offering for resale by such selling
stockholders in a subsequent prospectus supplement. However, the selling stockholders may sell or
transfer all or a portion of their shares of our common stock pursuant to any available exemption
from the registration requirements of the Securities Act of 1933, as amended.
Certain Relationships and Related Party Transactions
Investor Rights Agreement
Pursuant to a third amended and restated investor rights agreement, dated as of September 13,
2006, by and among entities who held our redeemable convertible preferred stock (which was
converted to common stock at our initial public offering) and us, we granted registration rights to
all such holders, to Mount Sinai School of Medicine of New York University, or MSSM, and to the
holder of a warrant which has since been exercised. Entities affiliated with Prospect Venture
Partners II, L.P., New Enterprise Associates, Frazier Healthcare Ventures, Canaan Equity, Quaker
BioVentures, CHL Medical Partners and Palo Alto Investors, LLC, each a holder of 5% or more of our
voting securities, and their affiliates are parties to this investor rights agreement.
Subject to certain limitations, these stockholders may demand that, on up to two occasions, we
register all or part of their securities for sale under the Securities Act as long as the aggregate
price to the public for the securities to be sold in each instance is $5,000,000 or more. If we
are eligible to register any of our common stock on Form S-3, these stockholders may make the same
demand; provided, however, that we will not be required to register their securities if (i) we have
already effected a registration within 90 days prior to the request or have effected two or more
registrations on Form S-3 within the preceding 12 month period, or (ii) if the aggregate price to
the public for the securities to be sold is less than $2,500,000. Additionally, if we believe that
such registration would have a materially detrimental effect on any material corporate event, we
may delay the request for up to three months, but not more than once in any twelve month period.
These stockholders may also request registration of their shares if we register any of our
common stock, either for our own account or for the account of other securityholders. In such an
event, these stockholders are entitled to notice of the registration and to include their shares of
common stock in such registration. In the case of an underwritten registration, we must use our
reasonable best efforts to obtain the permission of the underwriters to the inclusion of the
holders shares in the offering on the same terms.
With specified exceptions, a holders right to include shares in a registration is subject to
the right of the underwriters to limit the number of shares included in the offering. All fees,
costs and expenses of any registrations will generally be paid by us.
Mt. Sinai School of Medicine License Agreement
We acquired exclusive worldwide patent rights to develop and commercialize our lead products
and other pharmacological chaperones pursuant to a license agreement with MSSM. In connection with
this agreement, we issued 232,266 shares of our common stock to MSSM in April 2002. In October 2006
we issued MSSM an additional 133,333 shares of common stock and made a payment of $1.0 million in
consideration of an expanded field of use under that license. Under this agreement, to date we have
paid no upfront or annual license fees and we have no milestone or future payments other than
royalties on net sales. However, on October 31, 2008, we amended and restated this license
agreement to, among other items, provide us with the sole right to control the prosecution of
patent rights under such agreement and to clarify the portion of royalties and milestone payments
we receive from Shire Pharmaceuticals Ireland Ltd. that are payable to MSSM. In connection
therewith, we agreed to pay MSSM $2.6 million in connection with the $50 million upfront payment
that we received in November 2007 from Shire and an additional $2.6 million for the sole right to
and control over the prosecution of patent rights. This agreement expires upon expiration of the
last of the licensed patent rights, which will be in 2019 if a foreign patent is granted and 2018
otherwise, or later subject to any patent term extension that may be granted.
-5-
PLAN OF DISTRIBUTION
Amicus, and any selling stockholders and their successors, including their permitted
transferees, may sell the offered securities in any of the ways described below or in any
combination or any other way set forth in an applicable prospectus supplement from time to time:
|
|
|
to or through underwriters or dealers; |
|
|
|
|
through one or more agents; or |
|
|
|
|
directly to purchasers or to a single purchaser. |
The distribution of the securities may be effected from time to time in one or more
transactions:
|
|
|
at a fixed price, or prices, which may be changed from time to time; |
|
|
|
|
at market prices prevailing at the time of sale; |
|
|
|
|
at prices related to such prevailing market prices; or |
|
|
|
|
at negotiated prices. |
Each prospectus supplement will describe the method of distribution of the securities and any
applicable restrictions.
The prospectus supplement with respect to the securities of a particular series will describe
the terms of the offering of the securities, including the following:
|
|
|
the name or names of any underwriters, dealers or agents and the
amounts of securities underwritten or purchased by each of them; |
|
|
|
|
the public offering price of the securities and the proceeds to us and
any discounts, commissions or concessions allowed or reallowed or paid
to dealers; and |
|
|
|
|
any securities exchanges on which the securities may be listed. |
Any offering price and any discounts or concessions allowed or reallowed or paid to dealers
may be changed from time to time.
Only the agents or underwriters named in each prospectus supplement are agents or underwriters
in connection with the securities being offered thereby.
We may authorize underwriters, dealers or other persons acting as our agents to solicit offers
by certain institutions to purchase securities from us pursuant to delayed delivery contracts
providing for payment and delivery on the date stated in each applicable prospectus supplement.
Each contract will be for an amount not less than, and the aggregate amount of securities sold
pursuant to such contracts shall not be less nor more than, the respective amounts stated in each
applicable prospectus supplement. Institutions with whom the contracts, when authorized, may be
made include commercial and savings banks, insurance companies, pension funds, investment
companies, educational and charitable institutions and other institutions, but shall in all cases
be subject to our approval. Delayed delivery contracts will be subject only to those conditions set
forth in each applicable prospectus supplement, and each prospectus supplement will set forth any
commissions we pay for solicitation of these contracts.
Agents, underwriters and other third parties described above may be entitled to
indemnification by us or any selling stockholder against certain civil liabilities, including
liabilities under the Securities Act of 1933, or to contribution from us with respect to payments
which the agents, underwriters or other third parties may be required to make in respect thereof.
Agents, underwriters and such other third parties may be customers of, engage in transactions with,
or perform services for us in the ordinary course of business.
One or more firms, referred to as remarketing firms, may also offer or sell the securities,
if a prospectus supplement so indicates, in connection with a remarketing arrangement upon their
purchase. Remarketing firms will act as principals for their own accounts or as our agents. These
remarketing firms will offer or sell the securities in accordance with the terms of the securities.
Each prospectus supplement will identify and describe any remarketing firm and the terms of its
agreement, if any, with us and will describe the remarketing firms compensation. Remarketing firms
may be deemed to be underwriters in connection with the securities they remarket. Remarketing firms
may be entitled under agreements that may be entered into with us to indemnification by us against
-6-
certain civil liabilities, including liabilities under the Securities Act of 1933, and may be
customers of, engage in transactions with or perform services for us in the ordinary course of
business.
Certain underwriters may use this prospectus and any accompanying prospectus supplement for
offers and sales related to market-making transactions in the securities. These underwriters may
act as principal or agent in these transactions, and the sales will be made at prices related to
prevailing market prices at the time of sale.
The securities we or any selling stockholders offer may be new issues of securities and may
have no established trading market. The securities may or may not be listed on a securities
exchange. Underwriters may make a market in these securities, but will not be obligated to do so
and may discontinue any market making at any time without notice. We can make no assurance as to
the liquidity of, or the existence of trading markets for, any of the securities.
Certain persons participating in an offering may engage in overallotment, stabilizing
transactions, short covering transactions and penalty bids in accordance with rules and regulations
under the Securities Exchange Act of 1934. Overallotment involves sales in excess of the offering
size, which create a short position. Stabilizing transactions permit bids to purchase the
underlying security so long as the stabilizing bids do not exceed a specified maximum. Short
covering transactions involve purchases of the securities in the open market after the distribution
is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling
concession from a dealer when the securities originally sold by the dealer are purchased in a short
covering transaction to cover short positions. Those activities may cause the price of the
securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue
any of the activities at any time.
We also may sell any of the securities through agents designated by us from time to time. We
will name any agent involved in the offer or sale of these securities and will list commissions
payable by us to these agents in the applicable prospectus supplement. These agents will be acting
on a best efforts basis to solicit purchases for the period of its appointment, unless stated
otherwise in the applicable prospectuses.
We or any selling stockholders may sell any of the securities directly to purchasers. In this
case, we or any selling stockholders will not engage underwriters or agents in the offer and sale
of these securities.
-7-
GENERAL DESCRIPTION OF SECURITIES
We may offer and sell, at any time and from time to time:
|
|
|
Shares of our common stock; |
|
|
|
|
Shares of our preferred stock; |
|
|
|
|
Warrants to purchase shares of our common stock, preferred stock and/or debt
securities; |
|
|
|
|
Debt securities consisting of debentures, notes or other evidences of indebtedness;
or |
|
|
|
|
Any combination of these securities. |
The
selling stockholders may also offer shares of our common stock from time to
time. The terms of any securities we offer or offered by the selling stockholders will be
determined at the time of sale. We may issue debt securities that are exchangeable for and/or
convertible into common stock or any of the other securities that may be sold under this
prospectus. When particular securities are offered, a supplement to this prospectus will be filed
with the SEC, which will describe the terms of the offering and sale of the offered securities.
DESCRIPTION OF OUR COMMON STOCK
The following summary of the terms of our common stock is subject to and qualified in its
entirety by reference to our charter and by-laws, copies of which are on file with the SEC as
exhibits to previous SEC filings. Please refer to Where You Can Find More Information below for
directions on obtaining these documents.
As of May 11, 2009, we are authorized to issue 50,000,000 shares of common stock, $0.01 par
value per share. As of May 11, 2009, we had 22,643,334 shares of common stock outstanding.
General
Holders of our common stock are entitled to one vote for each share held on all matters
submitted to a vote of stockholders and do not have cumulative voting rights. An election of
directors by our stockholders shall be determined by a plurality of the votes cast by the
stockholders entitled to vote on the election. Holders of common stock are entitled to receive
proportionately any dividends as may be declared by our board of directors, subject to any
preferential dividend rights of any outstanding preferred stock.
In the event of our liquidation or dissolution, the holders of common stock are entitled to
receive proportionately all assets available for distribution to stockholders after the payment of
all debts and other liabilities and subject to the prior rights of any outstanding preferred stock.
Holders of common stock have no preemptive, subscription, redemption or conversion rights. The
rights, preferences and privileges of holders of common stock are subject to and may be adversely
affected by the rights of the holders of shares of any series of preferred stock that we may
designate and issue in the future.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is American Stock Transfer and Trust
Company.
The NASDAQ Global Market
Our common stock is listed on the Nasdaq Global Market under the symbol FOLD.
-8-
DESCRIPTION OF OUR PREFERRED STOCK
We are authorized to issue up to 10,000,000 shares of preferred stock, par value $0.01 per
share. As of May 11, 2009, there were no shares of our preferred stock outstanding.
Our board of directors may, without further action by our stockholders, from time to time,
direct the issuance of shares of preferred stock in series and may, at the time of issuance,
determine the rights, preferences and limitations of each series, including voting rights, dividend
rights and redemption and liquidation preferences. Satisfaction of any dividend preferences of
outstanding shares of our preferred stock would reduce the amount of funds available for the
payment of dividends on shares of our common stock. Holders of shares of our preferred stock may be
entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up
of our Company before any payment is made to the holders of shares of our common stock. In some
circumstances, the issuance of shares of preferred stock may render more difficult or tend to
discourage a merger, tender offer or proxy contest, the assumption of control by a holder of a
large block of our securities or the removal of incumbent management. Upon the affirmative vote of
our board of directors, without stockholder approval, we may issue shares of preferred stock with
voting and conversion rights which could adversely affect the holders of shares of our common
stock.
If we offer a specific class or series of preferred stock under this prospectus, we will
describe the terms of the preferred stock in the prospectus supplement for such offering and will
file a copy of the certificate establishing the terms of the preferred stock with the SEC. To the
extent required, this description will include:
|
|
|
the title and stated value; |
|
|
|
|
the number of shares offered, the liquidation preference per share and the purchase
price; |
|
|
|
|
the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation
for such dividends; |
|
|
|
|
whether dividends will be cumulative or non-cumulative and, if cumulative, the date
from which dividends will accumulate; |
|
|
|
|
the procedures for any auction and remarketing, if any; |
|
|
|
|
the provisions for a sinking fund, if any; |
|
|
|
|
the provisions for redemption, if applicable; |
|
|
|
|
any listing of the preferred stock on any securities exchange or market; |
|
|
|
|
whether the preferred stock will be convertible into our common stock, and, if
applicable, the conversion price (or how it will be calculated), the conversion period and
any other terms of conversion (including any anti-dilution provisions, if any); |
|
|
|
|
whether the preferred stock will be exchangeable into debt securities, and, if
applicable, the exchange price (or how it will be calculated), the exchange period and any
other terms of exchange (including any anti-dilution provisions, if any); |
|
|
|
|
voting rights, if any, of the preferred stock; |
|
|
|
|
a discussion of any material U.S. federal income tax considerations applicable to the
preferred stock; |
|
|
|
|
the relative ranking and preferences of the preferred stock as to dividend rights and
rights upon liquidation, dissolution or winding up of the affairs of the Company; |
|
|
|
|
any material limitations on issuance of any class or series of preferred stock
ranking senior to or on a parity with the series of preferred stock as to dividend rights
and rights upon liquidation, dissolution or winding up of the Company; and |
|
|
|
|
any other affirmative, negative or other covenants or contractual rights which might
be attendant with the specific class or series of preferred stock. |
The preferred stock offered by this prospectus, when issued, will not have, or be subject to,
any preemptive or similar rights.
Transfer Agent and Registrar
The transfer agent and registrar for any series or class of preferred stock will be set forth
in each applicable prospectus supplement.
-9-
DESCRIPTION OF OUR WARRANTS
We may issue warrants to purchase shares of our common stock, preferred stock and/or debt
securities in one or more series together with other securities or separately, as described in each
applicable prospectus supplement. Below is a description of certain general terms and provisions of
the warrants that we may offer. Particular terms of the warrants will be described in the
applicable warrant agreements and the applicable prospectus supplement for the warrants.
The applicable prospectus supplement will contain, where applicable, the following terms of
and other information relating to the warrants:
|
|
|
the specific designation and aggregate number of, and the price at which we will
issue, the warrants; |
|
|
|
|
the currency or currency units in which the offering price, if any, and the exercise
price are payable; |
|
|
|
|
the designation, amount and terms of the securities purchasable upon exercise of the
warrants; |
|
|
|
|
if applicable, the exercise price for shares of our common stock and the number of shares of common stock to be received upon exercise of the warrants; |
|
|
|
|
if applicable, the exercise price for shares of our preferred stock, the number of
shares of preferred stock to be received upon exercise, and a description of that class or
series of our preferred stock; |
|
|
|
|
if applicable, the exercise price for our debt securities, the amount of our debt
securities to be received upon exercise, and a description of that series of debt
securities; |
|
|
|
|
the date on which the right to exercise the warrants will begin and the date on which
that right will expire or, if the warrants may not be continuously exercised throughout
that period, the specific date or dates on which the warrants may be exercised; |
|
|
|
|
whether the warrants will be issued in fully registered form or bearer form, in
definitive or global form or in any combination of these forms, although, in any case, the
form of a warrant included in a unit will correspond to the form of the unit and of any
security included in that unit; |
|
|
|
|
any applicable material U.S. federal income tax consequences; |
|
|
|
|
the identity of the warrant agent for the warrants and of any other depositaries,
execution or paying agents, transfer agents, registrars or other agents; |
|
|
|
|
the proposed listing, if any, of the warrants or any securities purchasable upon
exercise of the warrants on any securities exchange; |
|
|
|
|
if applicable, the date from and after which the warrants and the common stock,
preferred stock and/or debt securities will be separately transferable; |
|
|
|
|
if applicable, the minimum or maximum amount of the warrants that may be exercised at
any one time; |
|
|
|
|
information with respect to book-entry procedures, if any; |
|
|
|
|
the anti-dilution provisions of the warrants, if any; |
|
|
|
|
any redemption or call provisions; |
|
|
|
|
whether the warrants are to be sold separately or with other securities as parts of
units; and |
|
|
|
|
any additional terms of the warrants, including terms, procedures and limitations
relating to the exchange and exercise of the warrants. |
Transfer Agent and Registrar
The transfer agent and registrar for any warrants will be set forth in the applicable
prospectus supplement.
-10-
DESCRIPTION OF OUR DEBT SECURITIES
This section describes the general terms and provisions of the debt securities that we may
offer under this prospectus, any of which may be issued as convertible or exchangeable debt
securities. We will set forth the particular terms of the debt securities we offer in a prospectus
supplement. The extent, if any, to which the following general provisions apply to particular debt
securities will be described in the applicable prospectus supplement. The following description of
general terms relating to the debt securities and the indenture under which the debt securities
will be issued are summaries only and therefore are not complete. You should read the indenture and
the prospectus supplement regarding any particular issuance of debt securities.
We will issue any debt under an indenture to be entered into between us and the trustee
identified in the applicable prospectus supplement. The terms of the debt securities will include
those stated in the indenture and those made part of the indenture by reference to the Trust
Indenture Act of 1939, as in effect on the date of the indenture. We have filed or will file a copy
of the form of indenture as an exhibit to the registration statement in which this prospectus is
included. The indenture will be subject to and governed by the terms of the Trust Indenture Act of
1939.
We may offer under this prospectus up to an aggregate principal amount of $100,000,000 in debt
securities, or if debt securities are issued at a discount, or in a foreign currency, foreign
currency units or composite currency, the principal amount as may be sold for an initial public
offering price of up to $100,000,000. Unless otherwise specified in the applicable prospectus
supplement, the debt securities will represent direct, unsecured obligations of the Company and
will rank equally with all of our other unsecured indebtedness.
The following statements relating to the debt securities and the indenture are summaries,
qualified in their entirety by reference to the detailed provisions of the indenture and the final
form indenture as may be filed with a future prospectus supplement.
General
We may issue the debt securities in one or more series with the same or various maturities, at
par, at a premium, or at a discount. We will describe the particular terms of each series of debt
securities in a prospectus supplement relating to that series, which we will file with the SEC.
The prospectus supplement will set forth, to the extent required, the following terms of the
debt securities in respect of which the prospectus supplement is delivered:
|
|
|
the title of the series; |
|
|
|
|
the aggregate principal amount; |
|
|
|
|
the issue price or prices, expressed as a percentage of the aggregate principal
amount of the debt securities; |
|
|
|
|
any limit on the aggregate principal amount; |
|
|
|
|
the date or dates on which principal is payable; |
|
|
|
|
the interest rate or rates (which may be fixed or variable) or, if applicable, the
method used to determine such rate or rates; |
|
|
|
|
the date or dates from which interest, if any, will be payable and any regular
record date for the interest payable; |
|
|
|
|
the place or places where principal and, if applicable, premium and interest, is
payable; |
|
|
|
|
the terms and conditions upon which we may, or the holders may require us to, redeem
or repurchase the debt securities; |
|
|
|
|
the denominations in which such debt securities may be issuable, if other than
denominations of $1,000 or any integral multiple of that number; |
|
|
|
|
whether the debt securities are to be issuable in the form of certificated
securities (as described below) or global securities (as described below); |
|
|
|
|
the portion of principal amount that will be payable upon declaration of
acceleration of the maturity date if other than the principal amount of the debt
securities; |
|
|
|
|
the currency of denomination; |
|
|
|
|
the designation of the currency, currencies or currency units in which payment of
principal and, if applicable, premium and interest, will be made; |
-11-
|
|
|
if payments of principal and, if applicable, premium or interest, on the debt
securities are to be made in one or more currencies or currency units other than the
currency of denomination, the manner in which the exchange rate with respect to such
payments will be determined; |
|
|
|
|
if amounts of principal and, if applicable, premium and interest may be determined
by reference to an index based on a currency or currencies or by reference to a
commodity, commodity index, stock exchange index or financial index, then the manner in
which such amounts will be determined; |
|
|
|
|
the provisions, if any, relating to any collateral provided for such debt
securities; |
|
|
|
|
any addition to or change in the covenants and/or the acceleration provisions
described in this prospectus or in the indenture; |
|
|
|
|
any events of default, if not otherwise described below under Events of Default; |
|
|
|
|
the terms and conditions, if any, for conversion into or exchange for shares of our
common stock or preferred stock; |
|
|
|
|
any depositaries, interest rate calculation agents, exchange rate calculation agents
or other agents; and |
|
|
|
|
the terms and conditions, if any, upon which the debt securities shall be
subordinated in right of payment to other indebtedness of the Company. |
We may issue discount debt securities that provide for an amount less than the stated
principal amount to be due and payable upon acceleration of the maturity of such debt securities in
accordance with the terms of the indenture. We may also issue debt securities in bearer form, with
or without coupons. If we issue discount debt securities or debt securities in bearer form, we will
describe material U.S. federal income tax considerations and other material special considerations
which apply to these debt securities in the applicable prospectus supplement.
We may issue debt securities denominated in or payable in a foreign currency or currencies or
a foreign currency unit or units. If we do, we will describe the restrictions, elections, and
general tax considerations relating to the debt securities and the foreign currency or currencies
or foreign currency unit or units in the applicable prospectus supplement.
Exchange and/or Conversion Rights
We may issue debt securities which can be exchanged for or converted into shares of our common
stock or preferred stock. If we do, we will describe the terms of exchange or conversion in the
prospectus supplement relating to these debt securities.
Transfer and Exchange
We may issue debt securities that will be represented by either:
|
|
|
book-entry securities, which means that there will be one or more global securities
registered in the name of a depositary or a nominee of a depositary; or |
|
|
|
|
certificated securities, which means that they will be represented by a certificate
issued in definitive registered form. |
We will specify in the prospectus supplement applicable to a particular offering whether the
debt securities offered will be book-entry or certificated securities.
Certificated Debt Securities
If you hold certificated debt securities issued under an indenture, you may transfer or
exchange such debt securities in accordance with the terms of the indenture. You will not be
charged a service charge for any transfer or exchange of certificated debt securities but may be
required to pay an amount sufficient to cover any tax or other governmental charge payable in
connection with such transfer or exchange.
Global Securities
The debt securities of a series may be issued in the form of one or more global securities
that will be deposited with a depositary or its nominees identified in the prospectus supplement
relating to the debt securities. In such a case, one or more global securities will be issued in a
denomination or aggregate denominations equal to the portion of the aggregate principal amount of
outstanding debt securities of the series to be represented by such global security or securities.
Unless and until it is exchanged in whole or in part for debt securities in definitive
registered form, a global security may not be registered for transfer or exchange except as a whole
by the depositary for such global security to a nominee of the depositary and except in the
circumstances described in the prospectus supplement relating to the debt securities. The specific
terms of the depositary
-12-
arrangement with respect to a series of debt securities will be described in the prospectus
supplement relating to such series.
No Protection in the Event of Change of Control
Any indenture that governs our debt securities covered by this prospectus may not have any
covenant or other provision providing for a put or increased interest or otherwise that would
afford holders of our debt securities additional protection in the event of a recapitalization
transaction, a change of control of the Company, or a highly leveraged transaction. If we offer any
covenants or provisions of this type with respect to any debt securities covered by this
prospectus, we will describe them in the applicable prospectus supplement.
Covenants
Unless otherwise indicated in this prospectus or the applicable prospectus supplement, our
debt securities may not have the benefit of any covenant that limits or restricts our business or
operations, the pledging of our assets or the incurrence by us of indebtedness. We will describe in
the applicable prospectus supplement any material covenants in respect of a series of debt
securities.
Consolidation, Merger and Sale of Assets
We may agree in any indenture that governs the debt securities of any series covered by this
prospectus that we will not consolidate with or merge into any other person or convey, transfer,
sell or lease our properties and assets substantially as an entirety to any person, unless such
person and such proposed transaction meets various criteria, which we will describe in detail in
the applicable prospectus supplement.
Defaults and Notice
The debt securities of any series will contain events of default to be specified in the
applicable prospectus supplement, which may include, without limitation:
|
|
|
failure to pay the principal of, or premium or make-whole amount, if any, on any
debt security of such series when due and payable (whether at maturity, by call for
redemption, through any mandatory sinking fund, by redemption at the option of the
holder, by declaration or acceleration or otherwise); |
|
|
|
|
failure to make a payment of any interest on any debt security of such series when
due; |
|
|
|
|
our failure to perform or observe any other covenants or agreements in the indenture
with respect to the debt securities of such series; |
|
|
|
|
certain events relating to our bankruptcy, insolvency or reorganization; and |
|
|
|
|
certain cross defaults, if and as applicable. |
If an event of default with respect to debt securities of any series shall occur and be
continuing, we may agree that the trustee or the holders of at least 25% in aggregate principal
amount of the then outstanding debt securities of such series may declare the principal amount (or,
if the debt securities of such series are issued at an original issue discount, such portion of the
principal amount as may be specified in the terms of the debt securities of such series) of all
debt securities of such series or such other amount or amounts as the debt securities or
supplemental indenture with respect to such series may provide, to be due and payable immediately.
Any provisions pertaining to events of default and any remedies associated therewith will be
described in the applicable prospectus supplement.
Any indenture that governs our debt securities covered by this prospectus may require that the
trustee under such indenture shall, within 90 days after the occurrence of a default, give to
holders of debt securities of any series notice of all uncured defaults with respect to such series
known to it. However, in the case of a default that results from the failure to make any payment of
the principal of, premium or make-whole amount, if any, or interest on the debt securities of any
series, or in the payment of any mandatory sinking fund installment with respect to debt securities
of such series, if any, the trustee may withhold such notice if it in good faith determines that
the withholding of such notice is in the interest of the holders of debt securities of such series.
Any terms and provisions relating to the foregoing types of provisions will be described in
further detail in the applicable prospectus supplement.
Any indenture that governs our debt securities covered by this prospectus will contain a
provision entitling the trustee to be indemnified by holders of debt securities before proceeding
to exercise any trust or power under the indenture at the request of such holders. Any such
indenture may provide that the holders of at least a majority in aggregate principal amount of the
then outstanding debt securities of any series may direct the time, method and place of conducting
any proceedings for any remedy available to the trustee, or of exercising any trust or power
conferred upon the trustee with respect to the debt securities of such series. However, the
-13-
trustee under any such indenture may decline to follow any such direction if, among other
reasons, the trustee determines in good faith that the actions or proceedings as directed may not
lawfully be taken, would involve the trustee in personal liability or would be unduly prejudicial
to the holders of the debt securities of such series not joining in such direction.
Any indenture that governs our debt securities covered by this prospectus may endow the
holders of such debt securities to institute a proceeding with respect to such indenture, subject
to certain conditions, which will be specified in the applicable prospectus supplement and which
may include, that the holders of at least a majority in aggregate principal amount of the debt
securities of such series then outstanding make a written request upon the trustee to exercise its
power under the indenture, indemnify the trustee and afford the trustee reasonable opportunity to
act. Even so, such holders may have an absolute right to receipt of the principal of, premium or
make-whole amount, if any, and interest when due, to require conversion or exchange of debt
securities if such indenture provides for convertibility or exchangeability at the option of the
holder and to institute suit for the enforcement of such rights. Any terms and provisions relating
to the foregoing types of provisions will be described in further detail in the applicable
prospectus supplement.
Modification of the Indenture
We and the trustee may modify any indenture that governs our debt securities of any series
covered by this prospectus with or without the consent of the holders of such debt securities,
under certain circumstances to be described in a prospectus supplement.
Defeasance; Satisfaction and Discharge
The prospectus supplement will outline the conditions under which we may elect to have certain
of our obligations under the indenture discharged and under which the indenture obligations will be
deemed to be satisfied.
Regarding the Trustee
We will identify the trustee and any relationship that we may have with such trustee, with
respect to any series of debt securities, in the prospectus supplement relating to the applicable
debt securities. You should note that if the trustee becomes a creditor of Amicus, the indenture
and the Trust Indenture Act of 1939 limit the rights of the trustee to obtain payment of claims in
certain cases, or to realize on certain property received in respect of any such claim, as security
or otherwise. The trustee and its affiliates may engage in, and will be permitted to continue to
engage in, other transactions with us and our affiliates. If, however, the trustee acquires any
conflicting interest within the meaning of the Trust Indenture Act of 1939, it must eliminate
such conflict or resign.
Governing Law
The law governing the indenture and the debt securities will be identified in the prospectus
supplement relating to the applicable indenture and debt securities.
-14-
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements and other information with the
SEC. You may read and copy information filed by us with the SEC at the SECs public reference
section, 100 F Street, N.E., Washington, D.C. 20549. Information regarding the operation of the
public reference section can be obtained by calling 1-800-SEC-0330. The SEC also maintains an
Internet site at http://www.sec.gov that contains reports, statements and other information about
issuers, such as us, who file electronically with the SEC. We maintain an Internet site at
http://www.amicustherapeutics.com. However, the information on our Internet site is not
incorporated by reference in this prospectus and any prospectus supplement and you should not
consider it a part of this prospectus or any accompanying prospectus supplement.
The SEC allows us to incorporate by reference into this prospectus the information in other
documents that we file with it. This means that we can disclose important information to you by
referring you to those documents. The information incorporated by reference is considered to be a
part of this prospectus, and information in documents that we file later with the SEC will
automatically update and supersede information contained in documents filed earlier with the SEC or
contained in this prospectus. We incorporate by reference in this prospectus the documents listed
below and any future filings that we may make with the SEC under Sections 13(a), 13(c), 14, or
15(d) of the Securities Exchange Act of 1934, as amended, prior to the termination of the offering
under this prospectus; provided, however, that we are not incorporating, in each case, any
documents or information deemed to have been furnished and not filed in accordance with SEC rules:
|
|
|
Our Annual Report on Form 10-K for the year ended December 31, 2008 (File
No. 001-33497) and our Quarterly Report for the period ended March 31, 2009 (File No. 001-33497); |
|
|
|
|
Our Current Reports on Form 8-K filed on January 8, 2009, February 18, 2009 and
February 27, 2009 (excluding any information furnished in such reports under exhibit 99.1
thereto); and |
|
|
|
|
The description of our common stock contained in our registration statement on Form
8-A (File No. 001-33497) filed May 23, 2007, under the Exchange Act, including any
amendment or report filed for the purpose of updating such description. |
You may obtain a copy of any or all of the documents referred to above which may have been or
may be incorporated by reference into this prospectus, except for exhibits to those documents
(unless the exhibits are specifically incorporated by reference into those documents) at no cost to
you by writing or telephoning us at the following address: Office of the Corporate Secretary,
Amicus Therapeutics, Inc., 6 Cedar Brook Drive, Cranbury, NJ 08512, telephone (609)-662-2000.
LEGAL MATTERS
The validity of the issuance of the securities offered hereby will be passed upon for us by
Bingham McCutchen LLP, Boston, Massachusetts. As appropriate, legal counsel representing the
selling stockholders, underwriters, dealers or agents will be named in the accompanying prospectus
supplement and may opine to certain legal matters.
EXPERTS
Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated
financial statements included in our Annual Report on Form 10-K for the year ended December 31,
2008, as set forth in their report, which is incorporated by reference in the prospectus and
elsewhere in this registration statement. Our consolidated financial statements are incorporated by
reference in reliance on Ernst & Young LLPs report, given on their authority as experts in
accounting and auditing.
-15-
PART II
INFORMATION NOT REQUIRED IN THE PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
Set forth below is an estimate (except in the case of the registration fee) of the amount of
fees and expenses to be incurred in connection with the issuance and distribution of the offered
securities registered hereby, other than underwriting discounts and commission, if any, incurred in
connection with the sale of the offered securities. All such amounts will be borne by Amicus
Therapeutics, Inc.
|
|
|
|
|
SEC Registration Fee |
|
$ |
5,580 |
|
Legal Fees and Expenses |
|
$ |
150,000 |
|
Accounting Fees and Expenses |
|
$ |
25,000 |
|
Blue Sky Fees and Expenses |
|
$ |
20,000 |
|
Printing Expenses |
|
$ |
10,000 |
|
Miscellaneous Fees and Expenses |
|
$ |
15,000 |
|
|
|
|
|
Total: |
|
$ |
225,580 |
|
|
|
|
|
Item 15. Indemnification of Directors and Officers.
Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the
personal liability of directors of a corporation to the corporation or its stockholders for
monetary damages for a breach of fiduciary duty as a director, except where the director breached
his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or
knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in
violation of Delaware corporate law or obtained an improper personal benefit. The Registrants
restated certificate of incorporation provides that no director of the Registrant shall be
personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty
as director, notwithstanding any provision of law imposing such liability, except to the extent
that the Delaware General Corporation Law prohibits the elimination or limitation of liability of
directors for breaches of fiduciary duty.
Section 145 of the Delaware General Corporation Law provides that a corporation has the power
to indemnify any person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative, by reason of the fact that the person is or was a director,
officer, employee or agent of the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses (including attorneys fees), judgments, fines
and amounts paid in settlements actually and reasonably incurred by the person in connection with
an action, suit or proceeding to which he or she is or is threatened to be made a party by reason
of such position, if such person acted in good faith and in a manner he or she reasonably believed
to be in or not opposed to the best interests of the corporation, and, in any criminal action or
proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the
case of actions brought by or in the right of the corporation, no indemnification shall be made
with respect to any claim, issue or matter as to which such person shall have been adjudged to be
liable to the corporation unless and only to the extent that the Delaware Court of Chancery or
other adjudicating court determines that, despite the adjudication of liability but in view of all
of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for
such expenses which the Delaware Court of Chancery or such other court shall deem proper.
The Registrants restated certificate of incorporation provides that the Registrant will, to
the fullest extent permitted by Section 145 of the Delaware General Corporation Law and the
Registrants by-laws (each as amended from time to time), indemnify each person who was or is a
party or is threatened to be made a party to any threatened, pending or completed action, suit or
proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he
or she is or was, or has agreed to become, a director or officer of the Registrant, or is or was
serving, or has agreed to serve, at the request of the Registrant, as a director, officer, partner,
or trustee of, or in a similar capacity with, another corporation, partnership, joint venture,
trust or other enterprise, including any employee benefit plan (all such persons being referred to
hereafter as an Indemnitee), or by reason of any action alleged to have been taken or omitted in
such capacity, against all expenses (including attorneys fees), judgments, fines and amounts paid
in settlement actually and reasonably incurred by, or on behalf of, the Indemnitee in connection
with such action, suit or proceeding and any appeal therefrom. Such indemnification may include
payment by the Registrant of expenses in defending an action or proceeding in advance of the final
disposition of such action or proceeding upon receipt of an undertaking by the Indemnitee (such
undertaking acceptable by the Registrant without reference to the financial ability of the
Indemnitee) to repay such payment if it is ultimately determined that the Indemnitee is not
entitled to indemnification under the Registrants restated certificate of incorporation; however,
the Registrant will not indemnify any person seeking indemnification in connection with a
proceeding (or part thereof) initiated by such person, unless such initiation was approved by the
Registrants board of directors. Also, the indemnification rights provided in the Registrants
restated certificate of incorporation (i) are not exclusive of any other rights to which those
indemnified may be
II-1
entitled under any law, agreement or vote of stockholders or disinterested directors or
otherwise, and (ii) will inure to the benefit of the heirs, executors and administrators of such
persons. The Registrant may, to the extent authorized from time to time by its board of directors,
grant indemnification rights to other employees of the Registrant or other persons serving the
Registrant and such rights may be equivalent to, or greater or less than, those set forth in the
Registrants restated certificate of incorporation.
The Registrant has entered into indemnification agreements with each of its directors. These
agreements, among other things, require the Registrant to indemnify each director to the fullest
extent permitted by Delaware law, including indemnification of expenses such as attorneys fees,
judgments, fines and settlement amounts incurred by the director in any action or proceeding,
including any action or proceeding by or in right of the Registrant, arising out of the persons
services as a director.
The Registrant maintains a general liability insurance policy that covers certain liabilities
of the Registrants directors and officers arising out of claims based on acts or omissions in
their capacities as directors or officers.
In any underwriting agreement that the Registrant enters into in connection with the sale of
common stock being registered hereby, the underwriters will agree to indemnify, under certain
conditions, the Registrant, its directors, its officers and persons who control the Registrant
within the meaning of the Securities Act, against certain liabilities.
II-2
Item 16. Exhibits
|
|
|
Exhibit |
|
Description |
|
|
|
1.1* |
|
Form of underwriting / agency agreement |
|
|
|
4.1 |
|
Restated Certificate of Incorporation of the registrant
(incorporated by reference to Exhibit 3.2 of the registrants
Registration Statement on Form S-1 (Registration No. 333-141700),
as amended, originally filed with the SEC on May 17, 2007) |
|
|
|
4.2* |
|
Certificate of Designations |
|
|
|
4.3 |
|
Restated By-laws of the of the registrant (incorporated by
reference to Exhibit 3.4 of the registrants Registration
Statement on Form S-1/A (Registration No. 333-141700), as
amended, originally filed with the SEC on April 27, 2007) |
|
|
|
4.4 |
|
Specimen Stock Certificate evidencing shares of common stock
(incorporated by reference to Exhibit 4.1 of the registrants
Registration Statement on Form S-1 (Registration No. 333-141700),
as amended, originally filed with the SEC on March 30, 2007) |
|
|
|
4.5* |
|
Specimen Stock Certificate evidencing shares of preferred stock |
|
|
|
4.6 |
|
Third Amended and Restated Investor Rights Agreement, dated as of
September 13, 2006, as amended, by and among the registrant and
certain stockholders of the registrant (incorporated by reference
to Exhibit 4.3 of the registrants Registration Statement on Form
S-1 (Registration No. 333-141700), as amended, originally filed
with the SEC on March 30, 2007) |
|
|
|
4.7* |
|
Form of Common Stock Warrant Agreement and Warrant Certificate |
|
|
|
4.8* |
|
Form of Preferred Stock Warrant Agreement and Warrant Certificate |
|
|
|
4.9* |
|
Form of Debt Securities Warrant Agreement and Warrant Certificate |
|
|
|
4.10**
|
|
Form of Indenture |
|
|
|
5.1** |
|
Opinion of Bingham McCutchen LLP |
|
|
|
12.1** |
|
Statement re: Computation of Ratios |
|
|
|
23.1 |
|
Consent of Bingham McCutchen LLP (included in Exhibit 5.1) |
|
|
|
23.2 |
|
Consent of Ernst & Young LLP (filed herewith) |
|
|
|
24.1** |
|
Power of attorneyincluded on the signature page |
|
|
|
25.1 |
|
Statement of Eligibility of Trustee Under Debt Indenture (to be
filed separately pursuant to Section 305(b)(2) of the Trust
Indenture Act of 1939) |
|
|
|
* |
|
To be filed, if necessary, subsequent to the effectiveness of this
registration statement by an amendment to this registration statement
or incorporated by reference pursuant to a Current Report on Form 8-K
in connection with an offering of securities. |
|
** |
|
Previously filed with this Registration Statement on Form S-3 |
II-3
Item 17. Undertakings.
(a) The undersigned Registrant hereby undertakes:
(1) to file, during any period in which offers or sales are being made, a post-effective
amendment to this Registration Statement: (i) to include any prospectus required by
Section 10(a)(3) of the Securities Act; (ii) to reflect in the prospectus any facts or events
arising after the effective date of the Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the
information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar value of securities offered would not
exceed that which was registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with the Commission
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more
than a 20% change in the maximum aggregate offering price set forth in the Calculation of
Registration Fee table in the effective registration statement; and (iii) to include any material
information with respect to the plan of distribution not previously disclosed in the Registration
Statement or any material change to such information in the Registration Statement; provided,
however , that paragraphs (i), (ii) and (iii) do not apply if the Registration Statement is on
Form S-3 and the information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the Commission by the Registrant
pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are
incorporated by reference in the Registration Statement, or is contained in a form of prospectus
filed pursuant to Rule 424(b) that is part of the registration statement;
(2) that, for the purpose of determining any liability under the Securities Act of 1933, each
such post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof;
(3) to remove from registration by means of a post-effective amendment any of the securities
being registered which remain unsold at the termination of the offering;
(4) that, for the purpose of determining liability under the Securities Act of 1933 to any
purchaser:
(A) Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be
part of the registration statement as of the date the filed prospectus was deemed part of and
included in the registration statement; and
(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part
of a registration statement in reliance on Rule 430B relating to an offering made pursuant to
Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by
Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the
registration statement as of the earlier of the date such form of prospectus is first used after
effectiveness or the date of the first contract of sale of securities in the offering described in
prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is
at that date an underwriter, such date shall be deemed to be a new effective date of the
registration statement relating to the securities in the registration statement to which the
prospectus relates, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof. Provided, however , that no statement made in a
registration statement or prospectus that is part of the registration statement or made in a
document incorporated or deemed incorporated by reference into the registration statement or
prospectus that is part of the registration statement will, as to a purchaser with a time of
contract of sale prior to such effective date, supersede or modify any statement that was made in
the registration statement or prospectus that was part of the registration statement or made in any
such document immediately prior to such effective date; and
(5) that, for the purpose of determining liability of the Registrant under the Securities Act
of 1933 to any purchaser in the initial distribution of the securities, the undersigned Registrant
undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this
registration statement, regardless of the underwriting method used to sell the securities to the
purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned Registrant will be a seller to the purchaser and will be considered
to offer or sell such securities to such purchaser:
(i) Any preliminary prospectus or prospectus of the undersigned Registrant relating to the
offering required to be filed pursuant to Rule 424;
(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the
undersigned Registrant or used or referred to by the undersigned Registrant;
(iii) The portion of any other free writing prospectus relating to the offering containing
material information about the undersigned Registrant or its securities provided by or on behalf of
an undersigned Registrant; and
II-4
(iv) Any other communication that is an offer in the offering made by the undersigned
Registrant to the purchaser.
(b) The undersigned Registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act, each filing of Registrants annual report pursuant to
Section 13(a) or Section 15(d) of the Securities Exchange Act that is incorporated by reference in
this Registration Statement shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(c) The undersigned registrant hereby undertakes that: (i) for purposes of determining any
liability under the Securities Act of 1933, the information omitted from the form of prospectus
filed as part of the registration statement in reliance upon Rule 430A and contained in the form of
prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities
Act shall be deemed to be part of the registration statement as of the time it was declared
effective; and (ii) for the purpose of determining any liability under the Securities Act, each
post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.
(d) If and when applicable, the undersigned Registrant hereby undertakes to file an
application for the purpose of determining the eligibility of the trustee to act under subsection
(a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations
prescribed by the Securities and Exchange Commission under Section 305(b)(2) of the Act.
(e) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be
permitted to directors, officers and controlling persons of the registrant pursuant to the
provisions described under Item 15 above, or otherwise, the registrant has been advised that in the
opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such indemnification by it is against public policy
as expressed in the Act and will be governed by the final adjudication of such issue.
II-5
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant, Amicus
Therapeutics, certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on
its behalf by the undersigned, thereunto duly authorized, in the in the city of Cranbury, New
Jersey, on the 19th day of May, 2009.
|
|
|
|
|
|
|
|
|
AMICUS THERAPEUTICS, INC |
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ John F. Crowley
John F. Crowley
|
|
|
|
|
|
|
President and Chief Executive Officer |
|
|
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by
the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
/s/ John F. Crowley
(John F. Crowley)
|
|
Chief Executive Officer
(Principal Executive Officer)
|
|
May 19, 2009 |
|
|
|
|
|
/s/ James E. Dentzer
(James E. Dentzer)
|
|
Chief Financial Officer
(Principal Financial and
Accounting Officer)
|
|
May 19, 2009 |
|
|
|
|
|
|
|
Chairman of the Board
|
|
May 19, 2009 |
|
|
|
|
|
*
(Alexander E. Barkas, Ph.D.)
|
|
Director
|
|
May 19, 2009 |
|
|
|
|
|
|
|
Director
|
|
May 19, 2009 |
|
|
|
|
|
|
|
Director
|
|
May 19, 2009 |
|
|
*
(James N. Topper, M.D., Ph.D.)
|
|
Director
|
|
May 19, 2009 |
|
|
|
|
|
|
|
Director
|
|
May 19, 2009 |
|
|
|
|
|
*/s/
Geoffrey P.Gilmore
Name: Geoffrey P.Gilmore
Attorney-in-Fact
|
|
|
|
May 19, 2009 |
EXHIBIT INDEX
|
|
|
Exhibit |
|
Description |
|
|
|
1.1*
|
|
Form of underwriting / agency agreement |
|
|
|
4.1
|
|
Restated Certificate of Incorporation of the registrant
(incorporated by reference to Exhibit 3.2 of the registrants
Registration Statement on Form S-1 (Registration No. 333-141700),
as amended, originally filed with the SEC on May 17, 2007) |
|
|
|
4.2*
|
|
Certificate of Designations |
|
|
|
4.3
|
|
Restated By-laws of the of the registrant (incorporated by
reference to Exhibit 3.4 of the registrants Registration
Statement on Form S-1/A (Registration No. 333-141700), as
amended, originally filed with the SEC on April 27, 2007) |
|
|
|
4.4
|
|
Specimen Stock Certificate evidencing shares of common stock
(incorporated by reference to Exhibit 4.1 of the registrants
Registration Statement on Form S-1 (Registration No. 333-141700),
as amended, originally filed with the SEC on March 30, 2007) |
|
|
|
4.5*
|
|
Specimen Stock Certificate evidencing shares of preferred stock |
|
|
|
4.6
|
|
Third Amended and Restated Investor Rights Agreement, dated as of
September 13, 2006, as amended, by and among the registrant and
certain stockholders of the registrant (incorporated by reference
to Exhibit 4.3 of the registrants Registration Statement on Form
S-1 (Registration No. 333-141700), as amended, originally filed
with the SEC on March 30, 2007) |
|
|
|
4.7*
|
|
Form of Common Stock Warrant Agreement and Warrant Certificate |
|
|
|
4.8*
|
|
Form of Preferred Stock Warrant Agreement and Warrant Certificate |
|
|
|
4.9*
|
|
Form of Debt Securities Warrant Agreement and Warrant Certificate |
|
|
|
4.10**
|
|
Form of Indenture |
|
|
|
5.1**
|
|
Opinion of Bingham McCutchen LLP |
|
|
|
12.1**
|
|
Statement re: Computation of Ratios |
|
|
|
23.1
|
|
Consent of Bingham McCutchen LLP (included in Exhibit 5.1) |
|
|
|
23.2
|
|
Consent of Ernst & Young LLP (filed herewith) |
|
|
|
24.1** |
|
Power of attorneyincluded on the signature page |
|
|
|
25.1
|
|
Statement of Eligibility of Trustee Under Debt Indenture (to be
filed separately pursuant to Section 305(b)(2) of the Trust
Indenture Act of 1939) |
|
|
|
* |
|
To be filed, if necessary, subsequent to the effectiveness of this
registration statement by an amendment to this registration statement
or incorporated by reference pursuant to a Current Report on Form 8-K
in connection with an offering of securities. |
|
** |
|
Previously filed with this Registration Statement on Form S-3. |
EX-23.2
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption Experts
and to the use of our report dated February 4, 2009, in Amendment No. 1 to the Registration Statement
(Form S-3 No. 333-158405) and related Prospectus of Amicus Therapeutics.
/s/ Ernst & Young LLP
Metropark, New Jersey
May 15, 2009